Abstract: A poly(2,6-piperazinedione) liquid crystal alignment film providing high voltage holding ratio and high tilt angle when used in active matrix and super twisted nematic liquid crystal displays.
Type:
Grant
Filed:
December 2, 1993
Date of Patent:
May 28, 1996
Assignees:
E. I. Du Pont de Nemours and Company, Merck Patent GmbH
Inventors:
Brian C. Auman, Melvin P. Zussman, Edgar Bohm
Abstract: This invention relates to a novel protease-inhibitor,--which we called GELIN--and to pharmaceutical and cosmetic preparations thereof, containing this compound. GELIN is an inhibitor of human and porcine leucocyte elastase and chymotrypsin. GELIN has specific antibiotic properties. It also relates to the novel use of EGLIN, another chymotrypsin-inhibitor in cosmetic preparations.
Type:
Grant
Filed:
October 24, 1991
Date of Patent:
March 14, 1995
Assignee:
Merck Patent GmbH
Inventors:
Anthony Atkinson, Asgar Electricwala, Roy T. Sawyer, Nils von Sicard, Gerard Voerman
Abstract: Liquid crystal mixtures comprise one compound of the formula: ##STR1## wherein --A is selected from the group consisting of ##STR2## wherein R.sub.1 is independently C1-12 straight or branched alkyl or C1-12 straight or branched alkoxy and R.sub.2 is independently C1-12 straight or branched alkyl, X is selected from the group consisting of fluorine, chlorine, bromine, iodine and nitrile, and n is 1 or 2. The mixtures exhibit improved properties for image displays.
Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein R.sup.1, R.sup.2, A, Z, X and n are described in the specification.Compounds having the defined lateral substituents on the rings have a reduced tendency to form smectic phases as compared with the compounds not having such lateral substituents.
Abstract: A method of treating thrombosis with a pharmaceutical formulation comprising an endo-beta-glucuronidase, preferably leech-derived, heparin and a pharmacologically acceptable diluent, carrier or excipient which does not prevent the interaction between the heparin and the endo-beta-glucuronidase is disclosed. The formulation, which is disclosed, can also comprise a clot-lytic agent such as tissue plasminogen activator. Endo-beta-glucuronidase, unlike other hyaluronidases, has been found not to be inhibited by heparin.
Type:
Grant
Filed:
November 9, 1992
Date of Patent:
January 18, 1994
Assignee:
Merck Patent GmbH
Inventors:
Roy T. Sawyer, Christopher Powell-Jones
Abstract: The invention relates to an aqueous extract of the Acanthospermum hispidum plant and its use as a medicament. The extract is effective as an immunomodulator, in the remedy of radiation sickness, in the prophylaxis and therapy of virus diseases and in the prophylaxis and therapy of retroviral diseases in mammals, and has an antitumor effect.
Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein A is a cyclic radical selected from the group consisting of ##STR2## Z is selected from the group consisting of a single bond, a --CH2CH2-- group,n is 1 or 2,R.sup.1 and R.sup.2 are selected from the group consisting of C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy.
Abstract: Difluorobenzonitriles of the formula I ##STR1## in which Y is alkyl, alkenyl, alkoxy, oxaalkyl or alkenyloxy containing in each case 1 to 12 carbon atoms,one of the radicals A.sup.1 and A.sup.2 present in the molecule is ##STR2## where X is CH or N, and the other radical A.sup.1 or A.sup.2 is selected from the group comprising ##STR3## one of the radicals Z.sup.1 and Z.sup.2 is a single bond and the other radical Z.sup.1 or Z.sup.2 is --CH.sub.2 CH.sub.2 -- or a single bond, andm is 0 or 1, with the proviso that if m=1, Z.sup.1 =Z.sup.2 - single bond and one of the radicals A.sup.1 and A.sup.2 =2,5-pyrimidinediyl and the other radical A.sup.1 or A.sup.2 =1,4-phenylene, A.sup.1 is 2,5-pyrimidinediyl.
Type:
Grant
Filed:
November 19, 1990
Date of Patent:
April 20, 1993
Assignee:
Merck Patent GmbH
Inventors:
Volker Reiffenrath, Hans-Adolf Kurmeier, Bernhard Scheuble
Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein A is a cyclic radical selected from the group consisting of ##STR2## Z is selected from the group consisting of a single bond, a --CH2CH2-- group, a methyleneoxy group and an oxymethylene group,n is 1 or 2,p is 0, 1, or 2,r is 0 or 1,X is selected from the group consisting of fluorine, chlorine, bromine, iodine, nitrile and methyl,R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy and C.sub.1 -C.sub.12 -alkylamino and cyclic groups of the formulas ##STR3## wherein R.sup.3 through R.sup.6 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy, and C.sub.1 -C.sub.12 -alkylamino, and Z.sup.2 through Z.sup.
Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein A is a cyclic radical selected from the group consisting of ##STR2## Z is selected from the group consisting of a single bond, a --CH.sub.2 CH.sub.2 -- group, a methyleneoxy group and an oxymethylene group,n is 1 or 2,p is 0, 1, or 2,r is 0 or 1,X is selected from the group consisting of fluorine, chlorine, bromine, iodine, nitrile and methyl,R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy and C.sub.1 -C.sub.12 -alkylamino and cyclic groups of the formulas ##STR3## wherein R.sup.3 through R.sup.6 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy, and C.sub.1 -C.sub.12 -alkylamino, and Z.sup.2 through Z.sup.
Abstract: A device for inserting in wounds and wound cavities is described consisting of a container containing a pharmaceutical active substance, the walls of this container consisting at least partly of a membrane, preferably a semi-permeable membrane, which allows the active substance to escape into the wound area. The container is, more preferably, a dialysis tube. In order to drain off wound secretions, the container containing the pharmaceutically active substance, particularly taurolidine, is conveniently connected to a drainage tube. Preferably, a drainage tube is used in which the end which leads into the wound is split into filaments.
Abstract: Anisotropic compounds having a nematic phase have the formula ##STR1## wherein A is a cyclic radical selected from the group consisting of ##STR2## Z is selected from the group consisting of a single bond, a --CH2CH2-- group, a methyleneoxy group and an oxymethylene group,n is 1 or 2,p is 0, 1, or 2,r is 0 or 1,X is selected from the group consisting of fluorine, chlorine, bromine, iodine, nitrile and methyl,R.sup.1 and R.sup.2 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy and C.sub.1 -C.sub.12 -alkylamino and cyclic groups of the formulas ##STR3## wherein R.sup.3 through R.sup.6 are selected from the group consisting of hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -alkanoyloxy, and C.sub.1 -C.sub.12 -alkylamino, and Z.sup.2 through Z.sup.
Abstract: A liquid crystal composition comprising, as the essential components, trans-4-n-propyl-(4-ethylphenyl)-cyclohexane, trans-4-n-propyl-(4-cyanophenyl)-cyclohexane, trans-4-n-pentyl-(4-cyanophenyl)-cyclohexane, trans-4-n-pentyl-(4'-ethylbiphenyl-4)-cyclohexane and 4-(trans-4-n-pentylcyclohexyl)-4'-(trans-4-n-propylcyclohexyl)-biphenyl is drivable over a wide temperature range and can be operated rapidly at low temperatures.
Type:
Grant
Filed:
July 8, 1982
Date of Patent:
September 4, 1984
Assignees:
Hitachi, Ltd., Merck Patent GmbH
Inventors:
Shinji Hasegawa, Kazuhisa Toriyama, Ludwig Pohl, Georg Weber
Abstract: A liquid crystal composition comprising trans-4-n-propyl-(4-ethylphenyl)-cyclohexane, trans-4-n-pentyl-(4-cyanophenyl)-cyclohexane, trans-4-n-pentyl-(4' -ethylbiphenyl-4)cyclohexane, trans-4-n-pentyl-(4'-cyanobiphenyl-4)-cyclohexane, 4-n-propylphenyl-4-(trans-4-n-propylcyclohexyl)benzoate, and 4-(trans-4-n-pentyl-cyclohexyl)-4'-(trans-4-n-propylcyclohexyl)-biphenyl is drivable over a wide temperature range and can be operated rapidly at low temperatures.
Type:
Grant
Filed:
July 8, 1982
Date of Patent:
August 7, 1984
Assignees:
Hitachi, Ltd., Merck Patent GmbH
Inventors:
Shinji Hasegawa, Kazuhisa Toriyama, Ludwig Pohl, Georg Weber
Abstract: Anisotropic compounds of the formula (1) ##STR1## wherein X and Y are each hydrogen, C.sub.1 -C.sub.12 alkyl, C.sub.1 -C.sub.12 alkoxy, N-monoalkaylamine having 1 to 12 carbon atoms in the alkyl group, halogen, cyano, nitro, or a cyclic radical of the formula ##STR2## wherein R is hydrogen, halogen, cyano, nitro, C.sub.1 -C.sub.12 alkyl, or C.sub.1 -C.sub.12 alkoxy, Z.sup.1 is a --COO-- group or a --OOC-- group and Z.sup.2 may be the same as Z.sup.1 or a single convalent bond, with the proviso that:(a) only one of the groups X and Y is a cyclic radical, and(b) neither of the groups X or Y is hydrogen, bromine, or poperidino when the other is hydrogen, have low .DELTA.n-values without a greay tendency to form smectic phases and are useful in preparing liquid crystal devices.